Literature DB >> 1694291

Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.

J Bartek1, R Iggo, J Gannon, D P Lane.   

Abstract

The expression of the tumour suppressor gene p53 was analysed in 11 human breast cancer cell lines by immunohistochemistry, immunoprecipitation and cDNA sequencing. We used a panel of anti-p53 monoclonal antibodies for cell staining and found abnormalities in every case. Eight of the cell lines produce a form of p53 which can be immunoprecipitated by the monoclonal antibody PAb240 but not by PAb1620. In the murine system PAb240 only immunoprecipitates mutant p53. We sequenced p53 cDNA directly from four of the PAb240 positive cell lines using asymmetric PCR templates. All four contained missense mutations in p53 RNA, with no detectable expression of the wild type sequence. Different residues were affected in each cell line, but all the mutations changed amino acids conserved from man to Xenopus. These results imply that as in the murine system, the PAb240 antibody reliably detects a wide variety of p53 mutations and that these mutations have a common effect on the structure of p53. Immunohistochemical data suggest that p53 mutation is the commonest genetic alteration so far detected in primary breast cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694291

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  158 in total

1.  The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation.

Authors:  J T Zilfou; W H Hoffman; M Sank; D L George; M Murphy
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Immunohistochemical Detection of p53 and c-erbB-2 Proteins: Prognostic Significance in Operable Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1994-07-30       Impact factor: 4.239

3.  Immunophenotype of SV40-T gene transfected epithelial cell lines derived from human benign breast tumors.

Authors:  H Raux; P Planchon; F Chraibi-Hajji; V Magnien; V Sallé; D Brouty-Boyé
Journal:  In Vitro Cell Dev Biol       Date:  1992 Jul-Aug

4.  Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer.

Authors:  Mauricio P Pinto; Melanie M Badtke; Michelle L Dudevoir; J Chuck Harrell; Britta M Jacobsen; Kathryn B Horwitz
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

5.  The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.

Authors:  V Ashutosh Rao; Sarah R Klein; Keli K Agama; Eriko Toyoda; Noritaka Adachi; Yves Pommier; Emily B Shacter
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

6.  G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: phenotypes reversed by a tumorigenic mutation.

Authors:  J L Dai; R K Bansal; S E Kern
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

7.  Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation.

Authors:  H Haapasalo; J Isola; P Sallinen; H Kalimo; H Helin; I Rantala
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

8.  Expression of p53 product in Chinese human bladder carcinoma.

Authors:  D W Ye; J F Zheng; S X Qian; Y J Ma
Journal:  Urol Res       Date:  1993-05

9.  Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21.

Authors:  Y Hayashi; N Ishii; C Obayashi; K Jinnai; K Hanioka; Y Imai; H Itoh
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Pancreatic adenocarcinomas frequently show p53 gene mutations.

Authors:  A Scarpa; P Capelli; K Mukai; G Zamboni; T Oda; C Iacono; S Hirohashi
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.